Zoetis Inc. (ZTS) Free Cash Flow (FCF): $2.28B
The free cash flow (FCF) for Zoetis Inc. (ZTS) is $2.28B. It is below its 12-month average by 0.33% ($2.29B).
ZTS Free Cash Flow (FCF) Chart
ZTS Average Free Cash Flow (FCF) Chart
ZTS Current vs Average Free Cash Flow (FCF) Chart
ZTS Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$2.28B
FREE CASH FLOW (FCF) AVG TTM
$2.29B
FREE CASH FLOW (FCF) AVG 3Y
$1.88B
FREE CASH FLOW (FCF) AVG 5Y
$1.82B
FREE CASH FLOW (FCF) AVG 10Y
$1.43B
FREE CASH FLOW (FCF) AVG 15Y
$1.10B
FREE CASH FLOW (FCF) AVG 20Y
$1.03B
CURRENT VS TTM AVG
-0.33%
CURRENT VS 3Y AVG
+21.31%
CURRENT VS 5Y AVG
+25.24%
CURRENT VS 10Y AVG
+59.11%
CURRENT VS 15Y AVG
+108.36%
CURRENT VS 20Y AVG
+121.85%
FCF Analysis
Free Cash Flow (TTM)
$2.28B
FCF Yield
6.20%
Price/FCF
16.1
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Zoetis Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The free cash flow (FCF) for ZTS stock is $2.28B.
- What is the TTM average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The TTM average free cash flow (FCF) for ZTS stock is $2.29B.
- What is the 3Y average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The 3Y average free cash flow (FCF) for ZTS stock is $1.88B.
- What is the 5Y average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The 5Y average free cash flow (FCF) for ZTS stock is $1.82B.
- What is the 10Y average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The 10Y average free cash flow (FCF) for ZTS stock is $1.43B.
- What is the 15Y average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The 15Y average free cash flow (FCF) for ZTS stock is $1.10B.
- What is the 20Y average free cash flow (FCF) for Zoetis Inc. (ZTS)?
- The 20Y average free cash flow (FCF) for ZTS stock is $1.03B.
Zoetis Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $2.28B |
| 2024-12-31 | $2.30B |
| 2023-12-31 | $1.62B |
| 2022-12-31 | $1.33B |
| 2021-12-31 | $1.74B |
| 2020-12-31 | $1.67B |
| 2019-12-31 | $1.33B |
| 2018-12-31 | $1.45B |
| 2017-12-31 | $1.12B |
| 2016-12-31 | $497.00M |
| 2015-12-31 | $440.00M |
| 2014-12-31 | $431.00M |
| 2013-12-31 | $497.00M |
| 2012-12-31 | $328.00M |
| 2011-12-31 | $362.00M |
| 2010-12-31 | $130.00M |
| 2009-12-31 | $-37.00M |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck